Cinnamamide is an amide form of of trans-cinnamic acid and a metabolite of Streptomyces. Cinnamamide exhibits low cytotoxicity against BEL-7402 human hepatoma cells and HT-1080 fibrosarcoma cells and inhibits cell growth (IC50s = 1.94 and 1.29 mM, respectively). In vivo, cinnamamide (40 and 100 mg/kg, i.p.) reduces tumor weight in a mouse model of C26 murine colon carcinoma. Cinnamamide (75 and 150 mg/kg, i.p.) also reduces tumor weight in a mouse model of murine hepatoma 22 by 42% and 49%, respectively, without reducing body weight when delivered one or three days following tumor implantation. When presented with cinnamamide-treated food at a concentration of 0.8% w/w, house and wood mice food consumption is reduced to 32% and 17% of pretreatment levels, respectively, however, wood mouse consumption returns to pretrial levels by day two.